Centre for Virology, Vaccinology and Therapeutics Limited

Kin Hang Kok

Kwok Yung Yuen

Joy Yan Lam

The present invention relates to universal sarbecovirus vaccines that specifically express an interferon. This live universal sarbecovirus vaccine elicits mucosal immunity and heterotypic immunity against various sarbecoviruses, including SARS-CoV-1, SARS-CoV-2, and its variants. Interferon directly encoded from the genome of the live universal sarbecovirus overrides the virus-induced 'delayed type-I interferon', resulting in enhancement of mucosal T cell responses. The present invention further relates to uses of the vaccines for the preparation of pharmaceutical compositions, methods of treating or preventing viral infections, and kits comprising the vaccines.

Interferon-producing universal sarbecovirus vaccines, and uses thereof

The present application provides chimeric proteins comprising comprising a receptor binding domain ('RBD') of a SARS-CoV-2 spike protein (“S protein”) fused to a booster enhancer domain (“BED”) and uses thereof as vaccine or vaccine booster compositions. Also provided are method of boostering SARS-CoV-2 vaccines by administering to a vaccinated individual an effective amount of the vaccine booster composition, wherein the vaccine booster composition comprises a spike protein or a fragment thereof, and optionally wherein the vaccine booster composition is administered intranasally.

Growing community of inventors

Hong Kong, China

Kin Hang Kok